medigraphic.com

2001, Número 4

<< Anterior

Rev Mex Anest 2001; 24 (4)


Etofenamato: Características farmacologícas y clinicas de la formulación intramuscular

Herrera GL, Guevara LU, Torres GRA

Idioma: Español
Referencias bibliográficas: 45
Paginas:
Archivo PDF: 461.94 Kb.


RESUMEN

El etofenamato es un compuesto derivado del ácido flufenámico, que pertenece a los compuestos derivados del ácido antranílico. Éste se utilizó originalmente, como formulación para administración vía oral y, posteriormente, como crema o gel para administración tópica. Sin embargo, las características farmacológicas fueron mejoradas al hacer una combinación con triglicéridos de cadena media, generando un compuesto de administración intramuscular que mejoró el perfil terapéutico de este antiinflamatorio no esteroideo; destaca no sólo por inhibir la vía de las ciclooxigenasa sino que, en forma paralela, inhibe también la vía de la lipooxigenasa. Las características fisico-químicas, farmacológicas y clínicas son revisadas en este artículo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. DELL HD., FIELDLER J., JACOBI H., WAESCHE B. -On biochemistry and pharmacokinetics of etofenamate/Studies in man. -Arzneim-Forsch/Drug Res 1977; 27 (1), 6b:1322-5.

  2. DELL HD., BECKERMANN B., FIEDLER J., AND KAMP R.. -Renal elimination and metabolism of etofenamate after intramuscular administration of diferent doses to volunteers. -Arzneim-Forsch/Drug Res 1990; 40 (3):311-6.

  3. DELL HD., JACOBI H., WEASCHE B. -Biochemical studies on etofenamate. Experimental tests in animals. -Arzneim-Forsch/Drug Res 1977; 27 (6b):1316-21.

  4. PELSTER B., DELL HD. -Antiphlogistic and analgesic activity of etofenamate in laboratory animals after intramuscular administration. -Arzneim-Forsch/Drug Res 1990; 40 (3):297-300.

  5. JACOBI H., BREIER P., DELL HD., AND LORENZ D. - Pharmacology and toxicology of etofenamate 1st communication. -Arzneim-Forsch/Drug Res 1977; 27 (I) 6b:1326-33.

  6. JACOBI H., DELL HD., AND LORENZ D. -Pharmacology and toxicology of etofenamate 2nd communication. -Arzneim-Forsch/Drug Res 1977; 27(I) 6b:1333-40.

  7. Prolongation of the antiphlogistic/analgesic efficacy by intramusculary injected etofenamate. -2 nd world conference on inflammation antirheumatics, analgesics, inmunomodulators. Monte Carlo March 19-22 1986:A-115

  8. DELL HD., BECKERMANN B., KAMP R. -Pharmacokinetics and tolerability of etofenamate I.M. compared with I.M. NSAIDS in aquous solutions. -2 nd world conference on inflammation antirheumatics, analgesics, inmunomodulators. Monte Carlo March 19-22 1986;A-186.

  9. DELL HD., BRONS J., FIEDLER J., KAMP R., PELSTER B. -Animal experimental evidence of long-lasting liberation of etofenamate by half-life prolongation after intramuscular application. -Arzneim-Forsch/Drug Res 1990; 40 (3):300-5.

  10. BECKERMANN B., BOCK E., KAMP R., DELL HD. -Plasma level studies on volunteers after intramuscular application of different doses of etofenamate in oily solution. -Arzneim-Forsch/Drug Res 1990; 40 (3):305-11.

  11. GUYON B., ORY JP., DELACOUR JL., WAGSCHAL G., DAOUDAL P. -Renal Complications of Non-Steroid Anti-Inflammatory drugs. -Rev. Med. Interne 1983; 4 (2):189-198.

  12. BECKERMANN B., DELL HD., KAMP R. -Pharmacokinetics of etofenamate in oily solution, a new delivery system for I.M. application with prolonged drug liberation. -2 nd world conference on inflammation antirheumatics, analgesics, inmunomodulators. Monte Carlo March 19-22 1986; A-185

  13. KOEHLER G., TRESSEL W., DELL HD., LANGER M., WIRZBACH E. -Plasma, synovia, and tissue pharmacokinetics of etofenamate/ flufenamic acid in patients with rheumatoid arthritis after single administration of Rhemon I.M. -Hungarian Rheumatology 1991; 32(Suppl):P4-311.(Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  14. KOEHLER G., TRESSEL W., DELL HD., DOERSING M., et al. -Pharmacokinetic of etofenamte and flufenamic acid in plasma, synovia and tissues of patients with chronic polyarthritis after application of oily etofenamate solution. -Arzneim-Forsch/Drug Res 1992; 42 (12):1487-1491.

  15. KOEHLER G., DELL HD. -Pharmacokinetics and biochemical characteristics of etofenamate I.M. in patients with chronic polyarthritis. -Z Rheumatol 1986; 45 (4):185.

  16. BECKERMANN B., BOCK E., DELL HD., KOEHLER G., SEITZ I. -Study of the age and sex dependence of the pharmacokinetics of I.M. administered etofenamate. -Rheuma Schmerz Entzuendung 1991; 11 (2):3-14.

  17. DELL HD., FIEDLER J. -Elimination of etofenamate into milk. -Arch Pharm 1983; 316 (9):746-751.

  18. NIETSCH P. -Therapy with etofenamate I.M. -Kassernartz Verlag 1991.

  19. KRETZCHMAR. A. -Acemetacin and etofenamate. Drugs to keep your patients on the move. -A Satellite Symposium carried out on the ocassion of the XIXth ILAR Congress of Rheumatology organized by Troponwerke, Cologne, Germany in Singapore on June 9, 1997; 1-9.

  20. JACOBI H., BREIER P., DELL HD. -Pharmacology and Toxicology of Etofenamato 3rd Communication. -Arzneim-Forsch/Drug Res 1977; 27 (6b):1340–1349.

  21. ROBERT AL., FRANK KA., SOBERMAN RJ. -Leukotrienes and other products of the lipoxygenase pathway. -N Eng J Med 1990; 323 (10):645-55.

  22. BRAY MA. -Leukotrienes in Imflammation. -Agents Actions 1986; 19 (1-2):87–89.

  23. FRUCHTMANN R., KRUPKA U., PELSTER B. -Inhibition of lipoxygenase and cicloxygenase pathway of the arachidonic acid metabolism by etofenamate. -Akt Rheumatol 1984; 9:165-68.

  24. FRUCHTMANN R., KRUPKA U., PELSTER B. -Effects of anti-inflammatory drugs on the arachidonic acid metabolism. -III. Intern. Congress of Inflammation, Paris 1984; 3-7. Sept.

  25. KANKAANRANTA H., MOILANEN E. -Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes. -Molecular Pharmacology 1995; 47 (5):1006-13.

  26. KANKAANRANTA H., MOILANEN E. -Fenamates inhibit calcium entry in human neutrophils. -Scand J Rheumatol 1995 24 (3):191 Molecular Pharmacology 1995; 47 (5):1006-13.

  27. KANKAANRANTA H., LUOMALA M., KOSONEN O., MOILANEN E. Inhibition by fenamates of calcium influx and proliferation of human lymphocytes. -British Journal of Pharmacology 1996; 119:487-494.

  28. OHLROGGE R., PELSTER B., BERNARD I. -Efficacy and tissue-tolerability of etofenamate after I.M. injection. -Hungarian Rheumatology 1991; 32 (Suppl):4–312. (Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  29. PELSTER B. -Etofenamate in oily solution: new facilities for treatment of severe inflammation pain. -Br J Rheumatol; 1992; 31 (Suppl 2):157.

  30. FRICKE R., TAGHAWINEJAD M. -Nonsteroidal Antirheumatic drugs I.M. for treatment of secundary inflammatory reactions after chemical synovectomy with sodium morhulat. -EULAR Symposium Wien. 1985 9-12. Oct.

  31. PELSTER B. -Treatment of rheumatic diseases with etofenamate I.M., an injectable depot NSAID. -Rheumatol Eur 1996; 25 (Suppl 1):128.

  32. LEEB B., DELL HD. -Plasma and synovial fluid concentrations of etofenamate and flufenamic acid after multiple intramuscular injection of Rheumon R Depot in patientes with rheumatoid arthritis. -Hungarian Rheumatology 1991; 32 (Suppl):P4-310. (Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  33. PELSTER B. -Acute treatment of rheumatic diseases. Etofenamte I.M. as a short-term therapy. -Zeitschrift für Allgemeinmedizin 1993; 69 (16):440–4.

  34. FROMME K., KULLICH W., KLEIN G. -Parenteral use of etofenamte in lumbar syndromes. -Therapiewoche 1989; 4 (6):549–51

  35. MEYER-OVEN M., BENEKE M., BLUMBERGER W. -Onset of action and efficacy of etofenamte and diclofenac injectable solutions. -Hungarian Rheumatology 1991; 32 (Suppl):P4-314. (Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  36. STRATZ TH. -A comparison of etofenamate I.M. and diclofenac sodium I.M. in the treatment of acute lumbago. -Fortschr Med 1990; 108 (13):66–70.

  37. MIELKHE K. -Injection treatment of acute lumbal syndrome: comparison of etofenamate to diclofenac. -Therapiewoche 1990; 40 (7):462–5.

  38. SOUSA-MARQUEZ MJ. -Etofenamate in the treatment of renal colic. -Acta Urol Port 1996; 13 (1–4):43–6.

  39. PELSTER B., KOEHLER G., TRESSEL W. -Postoperative pain control by preoperative I.M. injection of etofenamate. -Poster XIII European Congress of Rheumatology, 18–23 June, 1995, Amsterdam, The Netherlands: 1995.

  40. PELSTER B., KOEHLER G., TRESSEL W. -Postoperatiove pain control by preoperative I.M. injection of etofenamate. -Rheumatol Europe 1995; 24 (Suppl 3) A-D235:287.

  41. PELSTER B., KOEHLER G., TRESSEL W. -Postoperatiove pain control by preoperatrive I.M. injection of etofenamate. -Topics Arthritis Rheum 1995; (2) 1-4.

  42. HOLZGREVE., STEDTFELD HW. -Postoperative therapy for pain and swelling: A double-blind study of I.M. etofenamate in comparison with a morphine derivate. -Medizinische Welt 1990; 41 (2):198–201.

  43. NIETSCH P. -Side effects and interactions during therapy with non-steroidal antirheumatics agents. -Medizinische Welt 1986; 37 (4):18–21.

  44. LEWIS JH. -Hepatic Toxicity of non-steroideal anti-inflammatory drugs. -Clin Pharm 1984; 3 (2):128-138

  45. DELL HD., BECKERMANN B., SEITZ J. -The advantages of oil-based intramuscular preparations of NSAIDS. -Therapiewoche 1991; 41 (43):2798–2803.




2020     |     www.medigraphic.com